Aa
Please Respond
Good evening to all...will someone please tell me the exact meanings of these three different types of responses to SOC tx
1.non-responder
2.nul-responder
3.rvr-responder
im just confused between the null and the non....also what really is a relapser...is it the virus returning after one month of tx...2 months?...is there a specific time frame....again...thanking all you good people in advance
1.non-responder
2.nul-responder
3.rvr-responder
im just confused between the null and the non....also what really is a relapser...is it the virus returning after one month of tx...2 months?...is there a specific time frame....again...thanking all you good people in advance
Hear hear!!
What are your thoughts on retreating a Gt3 who got a forced RVR via a PI trial? Do you think the standard 24 weeks apply or should they treat longer? A full year maybe, or perhaps a minimum of 24 weeks after UND?
Anxious to get feedback from anyone about this...
Cheers
M :)
What are your thoughts on retreating a Gt3 who got a forced RVR via a PI trial? Do you think the standard 24 weeks apply or should they treat longer? A full year maybe, or perhaps a minimum of 24 weeks after UND?
Anxious to get feedback from anyone about this...
Cheers
M :)
Gt3 is 'supposed' to be easier to treat - hurrrrmpfh - not from where I'm sitting!
I really wish eveyone including the Doctors would stop seeing G2s and G3s as easy to Treat.
We are only easy to treat when we RVR. With non RVR the response rate is pretty lousy. G1 RVR seem fairly easy to treat to me.
CS
I really wish eveyone including the Doctors would stop seeing G2s and G3s as easy to Treat.
We are only easy to treat when we RVR. With non RVR the response rate is pretty lousy. G1 RVR seem fairly easy to treat to me.
CS
thenumbers for late respondershave changed dramatically.
the were based on treating for only one year.
two new studies this year proved that treating late and super late responders out 1/2 year gave them the sames 50% chances of SVR that early responders have treating 1 year.
the key is to treat longer those whose virus is more persistant, and o try to maintain tx for 52-60 of UND before discontinuing tx. Done this way, even half the the difficult genotypes can achieve SVR.
mb
the were based on treating for only one year.
two new studies this year proved that treating late and super late responders out 1/2 year gave them the sames 50% chances of SVR that early responders have treating 1 year.
the key is to treat longer those whose virus is more persistant, and o try to maintain tx for 52-60 of UND before discontinuing tx. Done this way, even half the the difficult genotypes can achieve SVR.
mb
Canada, eh? Well, we're kinda related, being in the commonwealth and all!
I was on a PI trial (RO5024048 Roche/Pharmasset) in June this year which is how I got my forced RVR. I'm in follow up now and the protocol they have set for Gt3a's is 24 weeks only and hence the reluctance to extend treatment. There is very little info about retreating my geno, most of the studies and trials are for Gt1. Gt3 is 'supposed' to be easier to treat - hurrrrmpfh - not from where I'm sitting!
I was on a PI trial (RO5024048 Roche/Pharmasset) in June this year which is how I got my forced RVR. I'm in follow up now and the protocol they have set for Gt3a's is 24 weeks only and hence the reluctance to extend treatment. There is very little info about retreating my geno, most of the studies and trials are for Gt1. Gt3 is 'supposed' to be easier to treat - hurrrrmpfh - not from where I'm sitting!
Move to Canada?.....just kidding....looks like you do need to go longer for sure or get in on a protese inhibitor trial.
Thanks for that post, very succinct and very helpful. I was a null or non-responder last time, but they haven't differentiated so I'm going to fillow that up thanks to this post.
Back in 2004 they made me go the whole 24 weeks (I'm a Gt3a) despite not achieving an EVR at Week 12, pretty rough. I'm in re treatment now and got a forced RVR (PCR neg at 4 weeks) from a PI trial and I'm trying to push to treat for longer given my history.
I live in New Zealand and it's little harder here to get tailored treatment, they're still in to one size fits all. I know it will change but I hope it will change in the next few months!
Back in 2004 they made me go the whole 24 weeks (I'm a Gt3a) despite not achieving an EVR at Week 12, pretty rough. I'm in re treatment now and got a forced RVR (PCR neg at 4 weeks) from a PI trial and I'm trying to push to treat for longer given my history.
I live in New Zealand and it's little harder here to get tailored treatment, they're still in to one size fits all. I know it will change but I hope it will change in the next few months!
Terms For Response to HCV Treatment
Part of Hepatitis C: New Treatments in the Pipeline
By Tracy Swan
April 2008
Treatment Response: Response to hepatitis C treatment is measured by change in HCV viral load at different time points. Since it is a common practice to release interim data from HCV treatment trials, it is important to understand what these terms mean, so that interim results can be properly interpreted. It is important to consider the threshold of detection of the test used to measure HCV viral load, since these thresholds vary widely. The most sensitive tests can detect >5 copies IU/mL.
RVR (Rapid Virological Response): RVR means that there is no detectable hepatitis C virus in the blood after 4 weeks of treatment. An RVR is a good indication of SVR, but it is not as accurate for predicting who is unlikely to have SVR. Therefore, HCV treatment should not be discontinued if there is no RVR. RVR is mainly used in research.
EVR (Early Virological Response): EVR means that hepatitis C viral load has dropped by 99% (2 logs), or is undetectable after 12 weeks of HCV treatment. An EVR is a good predictor of the ultimate response to HCV treatment. If a person does not have an EVR, their chance of SVR is very low (1-4%). Usually, HCV treatment is discontinued in people who do not have an EVR.
ETR (End-of-Treatment Response): ETR means that there is no detectable hepatitis C virus in the blood at completion of HCV treatment. The ETR is usually higher than the SVR rate, because the hepatitis C virus may reappear in a person’s blood after completion of HCV treatment.
SVR (Sustained Virological Response): SVR means that there is no hepatitis C virus detectable in the blood six months after a person completes HCV treatment. Many experts regard SVR as a cure, and it is an indication of long-term remission. SVR rates are always lower than response rates from earlier time points.
SVR-12: SVR-12 means that there is no hepatitis C virus detectable in the blood 12 weeks after completion of HCV treatment. Although it has not been prospectively validated, many experts agree that relapse (meaning the emergence of detectable hepatitis C virus in blood after completion of treatment) is most likely to occur within 12 weeks. However, FDA and other regulatory agencies require 24 weeks of post-treatment follow-up before a person is considered to have achieved an SVR.
HCV Treatment History: There is a growing population of people who did not have a sustained virological response from HCV treatment. They are sometimes referred to as "treatment failures," but the term "treatment-experienced" is preferable, although both are not sufficiently specific.
It is important to know how treatment-experienced people responded to their first course of treatment, and the regimen that they were treated with, because these factors help to predict the likelihood of SVR from re-treatment. People initially treated with standard interferon, or standard interferon plus ribavirin, may achieve SVR when re-treated with pegylated interferon and ribavirin. Sometimes, HCV re-treatment trials study a mixed population of relapsers, partial responders, non-responders, and null responders, which makes it difficult to interpret the results.
Null Responder: A null responder is someone who achieves little or no decrease in hepatitis C viral load during HCV treatment. Null responders are highly unlikely to respond to re-treatment with an interferon-based regimen.
Non-responder: Often referred to as a "treatment failure," a non-responder is someone who does not have an EVR or, if they stay on treatment for 24 weeks, does not ever have a 2-log (99%) drop in hepatitis C viral load or undetectable HCV RNA during hepatitis C treatment.
Partial Responder: A partial responder is someone who experiences at least a 2-log decrease in hepatitis C viral load during HCV treatment. Partial responders are more likely to respond to re-treatment than non-responders or null responders.
Relapser: The term relapser refers to someone who has had an EVR or ETR, but whose virus rebounded after they completed HCV treatment. People who had a relapse after completing HCV treatment are more likely to achieve SVR after re-treatment than partial responders, non-responders, or null responders.
Part of Hepatitis C: New Treatments in the Pipeline
By Tracy Swan
April 2008
Treatment Response: Response to hepatitis C treatment is measured by change in HCV viral load at different time points. Since it is a common practice to release interim data from HCV treatment trials, it is important to understand what these terms mean, so that interim results can be properly interpreted. It is important to consider the threshold of detection of the test used to measure HCV viral load, since these thresholds vary widely. The most sensitive tests can detect >5 copies IU/mL.
RVR (Rapid Virological Response): RVR means that there is no detectable hepatitis C virus in the blood after 4 weeks of treatment. An RVR is a good indication of SVR, but it is not as accurate for predicting who is unlikely to have SVR. Therefore, HCV treatment should not be discontinued if there is no RVR. RVR is mainly used in research.
EVR (Early Virological Response): EVR means that hepatitis C viral load has dropped by 99% (2 logs), or is undetectable after 12 weeks of HCV treatment. An EVR is a good predictor of the ultimate response to HCV treatment. If a person does not have an EVR, their chance of SVR is very low (1-4%). Usually, HCV treatment is discontinued in people who do not have an EVR.
ETR (End-of-Treatment Response): ETR means that there is no detectable hepatitis C virus in the blood at completion of HCV treatment. The ETR is usually higher than the SVR rate, because the hepatitis C virus may reappear in a person’s blood after completion of HCV treatment.
SVR (Sustained Virological Response): SVR means that there is no hepatitis C virus detectable in the blood six months after a person completes HCV treatment. Many experts regard SVR as a cure, and it is an indication of long-term remission. SVR rates are always lower than response rates from earlier time points.
SVR-12: SVR-12 means that there is no hepatitis C virus detectable in the blood 12 weeks after completion of HCV treatment. Although it has not been prospectively validated, many experts agree that relapse (meaning the emergence of detectable hepatitis C virus in blood after completion of treatment) is most likely to occur within 12 weeks. However, FDA and other regulatory agencies require 24 weeks of post-treatment follow-up before a person is considered to have achieved an SVR.
HCV Treatment History: There is a growing population of people who did not have a sustained virological response from HCV treatment. They are sometimes referred to as "treatment failures," but the term "treatment-experienced" is preferable, although both are not sufficiently specific.
It is important to know how treatment-experienced people responded to their first course of treatment, and the regimen that they were treated with, because these factors help to predict the likelihood of SVR from re-treatment. People initially treated with standard interferon, or standard interferon plus ribavirin, may achieve SVR when re-treated with pegylated interferon and ribavirin. Sometimes, HCV re-treatment trials study a mixed population of relapsers, partial responders, non-responders, and null responders, which makes it difficult to interpret the results.
Null Responder: A null responder is someone who achieves little or no decrease in hepatitis C viral load during HCV treatment. Null responders are highly unlikely to respond to re-treatment with an interferon-based regimen.
Non-responder: Often referred to as a "treatment failure," a non-responder is someone who does not have an EVR or, if they stay on treatment for 24 weeks, does not ever have a 2-log (99%) drop in hepatitis C viral load or undetectable HCV RNA during hepatitis C treatment.
Partial Responder: A partial responder is someone who experiences at least a 2-log decrease in hepatitis C viral load during HCV treatment. Partial responders are more likely to respond to re-treatment than non-responders or null responders.
Relapser: The term relapser refers to someone who has had an EVR or ETR, but whose virus rebounded after they completed HCV treatment. People who had a relapse after completing HCV treatment are more likely to achieve SVR after re-treatment than partial responders, non-responders, or null responders.
EVR (Early Virological Response): EVR means that hepatitis C viral load has dropped by 99% (2 logs), or is undetectable after 12 weeks of HCV treatment. An EVR is a good predictor of the ultimate response to HCV treatment. If a person does not have an EVR, their chance of SVR is very low (1-4%). Usually, HCV treatment is discontinued in people who do not have an EVR.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
